Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard [...]

Vitamin D3 Potentiates Metformin in DU145 Human Prostate Cancer Cells

It is well established that common drugs like Metformin and vitamin D? exhibit a strong anti-proliferative action in many cancer cell lines. Recent research confirms that this is also true in human prostate cancer cells. In a recent study it was demonstrated that the combination of the two drugs, metformin and vitamin D3, had a [...]

“Do No Harm” NOT in Hippocratic Oath

I was talking to a prostate cancer patient about the difference between "harm" and "hurt," referring to the Hippocratic Oath.  Doctors are ok with "hurting" patients regarding impotence and incontinence, but do all they can to prevent "harm," or death.  Both of us agreed this distinction relates to the Hippocratic Oath.  But, turns out we [...]

By |2017-10-19T10:46:01-04:00November 15th, 2016|Uncategorized|0 Comments

Over 20,000 Have Pledged to Boycott CVS & Caremark until they sell Cancer Drugs Again- CVS removing many cancer drugs, including Xtandi, from it’s formulary

Sign pledge to boycott CVS here: http://bit.ly/2gAJlno CVS Pharmacy will hurt many cancer patients by removing dozens of cancer treatment drugs, like leukemia drug Tasigna, prostate cancer drug Xtandi and chemotherapy treatment drug Neupogen, from their formulary, starting in 2017. CVS claims these drugs cost too much. Go ahead and tell that to my insurance [...]

By |2020-02-04T10:08:32-05:00November 3rd, 2016|Advanced Prostate Cancer, Advocacy, Uncategorized|2 Comments

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate [...]

Go to Top